Download MendeleyNovel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota, A., Goto, M., Miyamoto, M., Nagashima, Y., Iwasaki, S., Komatsu, T., Momose, T., Yoshida, K., Tsukada, T., Matsufuji, T., Ohno, A., Suzuki, M., Ubukata, O., Kaneta, Y.(2022) Biochem Biophys Res Commun 621: 157-161
- PubMed: 35839742
- DOI: https://doi.org/10.1016/j.bbrc.2022.07.008
- Primary Citation of Related Structures:
7Y1G - PubMed Abstract:
Fibrolamellar hepatocellular carcinoma (FL-HCC) is known as a highly aggressive liver cancer that typically affects young adults without virus infection. Since this type of cancer does not respond to chemotherapy, surgery is the only known effective therapeutic option. Most FL-HCC patients express the fusion gene DNAJB1-PRKACA, which has been recognized as the signature of FL-HCC. It has also been reported that PRKACA kinase activity is essential for its oncogenic activity, suggesting that PRKACA kinase inhibition could be considered as an useful therapeutic target. In this study, we established an evaluation system for PRKACA kinase inhibitors and synthesized DS89002333, a novel PRKACA inhibitor. DS89002333 showed potent PRKACA inhibitory activity and inhibited fusion protein-dependent cell growth both in vitro and in vivo. Furthermore, this compound showed anti-tumor activity in an FL-HCC patient-derived xenograft model expressing the DNAJB1-PRKACA fusion gene. Our data suggest that DS89002333 could be considered as a potential therapeutic agent for FL-HCC.
Organizational Affiliation:
Daiichi Sankyo Co., Ltd., Shinagawa R&D Center, 1-2-5 Hiromachi, Shinagawa-ku, Tokyo, Japan. Electronic address: toyota.akiko.gy@daiichisankyo.co.jp.
